Repligen Co. (NASDAQ:RGEN) Shares Acquired by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 76.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,900 shares of the biotechnology company's stock after purchasing an additional 3,000 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Repligen were worth $993,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Slow Capital Inc. raised its position in shares of Repligen by 3.3% in the 4th quarter. Slow Capital Inc. now owns 16,760 shares of the biotechnology company's stock worth $2,412,000 after acquiring an additional 534 shares in the last quarter. Conestoga Capital Advisors LLC grew its stake in Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock valued at $136,395,000 after purchasing an additional 6,872 shares during the last quarter. Alliance Wealth Advisors LLC UT grew its stake in Repligen by 5.9% in the fourth quarter. Alliance Wealth Advisors LLC UT now owns 3,586 shares of the biotechnology company's stock valued at $516,000 after purchasing an additional 199 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Repligen by 46.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,629 shares of the biotechnology company's stock worth $2,679,000 after purchasing an additional 5,913 shares in the last quarter. Finally, Stephens Investment Management Group LLC raised its holdings in Repligen by 7.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after purchasing an additional 37,057 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

Shares of NASDAQ RGEN traded up $1.14 during mid-day trading on Thursday, hitting $122.32. The stock had a trading volume of 1,066,540 shares, compared to its average volume of 741,936. The firm has a market cap of $6.87 billion, a PE ratio of -239.84, a PEG ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a 50 day moving average of $128.58 and a two-hundred day moving average of $143.90. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. During the same period in the prior year, the company earned $0.28 earnings per share. The company's revenue was up 10.4% on a year-over-year basis. Research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of recent analyst reports. Royal Bank of Canada lowered their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research note on Tuesday, April 29th. JPMorgan Chase & Co. cut their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective for the company. Finally, Canaccord Genuity Group lowered their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

Insider Buying and Selling

In related news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.